RBC Capital raised the firm’s price target on Bausch + Lomb to $20 from $18 and keeps an Outperform rating on the shares ahead of its Q2 results next week. The performance will continue to be influenced by FX headwinds, though the focus will also fall on the company’s DED Rx drugs, new launches, and the impact from a recall in the surgical segment, the analyst tells investors in a research note. RBC adds that its updated price target reflect the re-rating of comps and to a lesser degree its updated outlook for the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb initiated with an Outperform at Raymond James
- Bausch + Lomb price target raised to $15.50 from $15 at Evercore ISI
- Bausch + Lomb Showcases Innovations at EuDEC 2024
- Bausch + Lomb Unveils New Daily Astigmatism Lenses
- Bausch + Lomb launches Infuse for Astigmatism daily disposable contacts in U.S.